The total return over the past 12 months is +22.33% vs. +19.98% for the S&P 500. So far it's up +11.49% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +18.64% | +18.64% | +17.66% | +14.54% | N/A | N/A |
| Total Return CAGR | +22.33% | +22.83% | +22.08% | +19.34% | N/A | N/A |
| Revenue CAGR | +10.39% | +4.75% | +3.69% | +10.03% | +9.52% | N/A |
| Net Income CAGR | +67.79% | (10.08%) | (1.07%) | +0.99% | +0.08% | N/A |
| EPS CAGR | +68.07% | (29.10%) | (2.79%) | (2.80%) | +0.80% | N/A |
| Free Cash Flow CAGR | +7.91% | (7.41%) | +0.11% | +9.93% | +9.56% | N/A |
| Operating Cash Flow CAGR | +1.16% | (8.59%) | (0.94%) | +9.10% | +9.35% | N/A |
| Dividends CAGR | +5.81% | +5.16% | +6.81% | +12.50% | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
AbbVie Inc. (ABBV)
| Year | Start price | End price | ABBV Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $228.49 | $248.86 | +11.49% | +13.55% | (2.06%) |
| 2025 | $177.70 | $228.49 | +33.13% | +17.72% | +15.41% |
| 2024 | $154.97 | $177.70 | +18.90% | +24.89% | (5.99%) |
| 2023 | $161.61 | $154.97 | (0.23%) | +26.19% | (26.42%) |
| 2022 | $135.40 | $161.61 | +24.04% | (18.17%) | +42.21% |
| 2021 | $107.15 | $135.40 | +32.40% | +28.74% | +3.66% |
| 2020 | $88.54 | $107.15 | +27.61% | +18.37% | +9.24% |
| 2019 | $92.19 | $88.54 | +1.50% | +31.22% | (29.72%) |
| 2018 | $96.71 | $92.19 | (0.98%) | (4.56%) | +3.58% |
| 2017 | $62.62 | $96.71 | +60.13% | +21.70% | +38.43% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
